Bayern Munich is actively evaluating the future of star midfielder Jamal Musiala, with club chief Karl-Heinz Rummenigge admitting the team is assessing whether to sell the 23-year-old due to persistent health issues. The decision follows a significant downturn in Musiala’s on-pitch performance, which has raised internal doubts about his ability to return to his previous elite level. Rummenigge stated that the club must responsibly manage the situation, noting that the financial implications of Musiala’s lucrative contract are becoming difficult to justify given his current form and medical status.
Rummenigge questions financial viability of star’s contract after neurological diagnosis
The controversy stems from Musiala’s diagnosis of a “neurological dysfunction” after suffering two on-pitch collapses during pre-season friendlies against Heidenheim and RB Leipzig. While the Germany international has publicly expressed optimism, stating there is “no additional health risk beyond this” and that the condition will not hamper his promising career, club officials remain cautious. Rummenigge told Sky Germany that current evidence suggests it will be “difficult for him to get back to the level he has often shown here in this stadium,” highlighting a stark contrast between the player’s personal reassurances and the club’s strategic concerns.
This potential transfer saga marks a pivotal moment for one of European football’s most highly rated young talents. Musiala’s “lofty salary” has become a central point of contention, with Rummenigge emphasizing that the club must consider how to deal with the financial burden if the player cannot consistently deliver top-tier output. As Bayern Munich navigates this complex medical and financial dilemma, the decision could set a precedent for how top clubs manage high-value assets facing long-term health uncertainties, potentially reshaping the transfer market landscape for elite young players.
Source: Yahoo Sports



